Get started
Author

Vera Buerger

Observed names: Buerger, Vera, V. Buerger
Institution: Valneva (Austria)
ORCID: 0009-0008-9884-1006
Observed ORCID: 0009-0008-9884-1006
OpenAlex ID: A5088615443
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
2023 · Martina Schneider, Marivic Narciso-Abraham, et al. · The Lancet · 255
PDF
Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41
2008 · Christoph S. Klade, Heiner Wedemeyer, et al. · Gastroenterology · 162
Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects
2006 · Christa Firbas, Bernd Jilma, et al. · Vaccine · 145
Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51
2010 · Katrin Dubischar-Kastner, Susanne Eder, et al. · Vaccine · 65
Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine
2010 · Christa Firbas, Thomas Boehm, et al. · Vaccine · 59
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study
2024 · Robert McMahon, Sebastian Toepfer, et al. · The Lancet Infectious Diseases · 52
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection
2024 · Whitney C. Weber, Zachary J. Streblow, et al. · Vaccines · 39
PDF
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults
2023 · Robert McMahon, Ulrike Fuchs, et al. · Journal of Travel Medicine · 38
PDF
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents
2024 · Vera Buerger, Sandra Hadl, et al. · The Lancet Infectious Diseases · 33
Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine
2024 · Gabriele Maurer, Vera Buerger, et al. · Journal of Travel Medicine · 17
PDF
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages
2025 · Karin Kosulin, Trevor L. Brasel, et al. · Emerging Microbes & Infections · 15
Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine
2024 · Vera Buerger, Gabriele Maurer, et al. · Journal of Travel Medicine · 15
PDF
Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ®)
2025 · Gabriele Maurer, Vera Buerger, et al. · Vaccines · 10
PDF
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil
2025 · Vera Buerger, Andrea Pfeiffer, et al. · The Lancet Infectious Diseases · 9
Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ®)
2026 · Natascha Sattler, Susanne Scheiblauer, et al. · Vaccine · 4
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial
2026 · Petronela Weisová, Susanne Scheiblauer, et al. · Nature Medicine · 3
Évaluation combinée de l'immunogénicité et de l'innocuité d'un nouveau candidat vaccin vivant-atténué à dose unique contre le chikungunya
2024 · H. Richez, V. Buerger, et al. · Médecine et Maladies Infectieuses Formation
Chikungunya : données de phase 3 sur l'innocuité et l'immunogénicité de VLA1553, un vaccin vivant-atténué à dose unique chez les adolescents au Brésil - Essai pivot
2024 · H. Richez, A. Pfeiffer, et al. · Médecine et Maladies Infectieuses Formation
Pharmacokinetics and safety of IV Injection of OCTA-C1-INH in hereditary angioedema
2020 · Vera Buerger, Sabine Poitschek · http://isrctn.com/
Su.56. Optimization of Schedule, Route and Adjuvant of Therapeutic Peptide Vaccines Against Hcv
2006 · Nicolas Sabarth, Christoph Klade, et al. · Clinical Immunology
Works count: 21
Citation count: 921
H-index: 12
I10-index: 13
Year
Topic
Type